



VCN Biosciences Announces Publication in Peer-Reviewed Journal of Immunotherapy of Cancer on Clinical Data obtained with VCN-01 after intratumorally administration in patients with Pancreatic Cancer

November, 2021 – VCN Biosciences, a clinical-stage company developing oncolytic immuno-oncology products today announced the publication of data from the Clinical Trial P-VCNA-002 conducted in patients with Pancreatic Cancer that received VCN-01 by intratumorally administration. The paper appears in Peer-Reviewed Journal of Immunotherapy of Cancer

Highlights from the article include:

- Treatment based in three intratumoral doses of VCN-01 is generally well-tolerated.
- VCN-01 treatment results in disease stabilization of injected lesions.
- VCN-01 is detected in blood as secondary peaks and in post-treatment tumor biopsies, indicating active virus replication.
- Patients present increasing levels of hyaluronidase in sera over time which confirm sustained intratumor VCN-01 replication
- VCN-01 decreases tumor stiffness in pancreatic patients, suggesting stromal disruption

Manel Cascalló, CEO of VCN Biosciences, said, “We are very excited to publish our clinical data obtained with VCN-01 by intratumor route in patients with pancreatic cancer. The product has demonstrated a good safety profile when combined with the standard chemotherapy for this tumor type, and we have been preliminary evidence of its capacity to control the growth of this extremely aggressive tumor. Although this trial was designed as a Proof of Concept study, it has allowed to confirm the mechanism of action of VCN-01 in the clinical setting. We also want to thank patients and families for their willingness to participate in the clinical trial.”

The publication is now available electronically at: [VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects | Journal for Immunotherapy of Cancer \(bmj.com\)](https://doi.org/10.1186/s12943-021-01488-8)

About VCN Biosciences

VCN Biosciences is a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses. VCN candidates are designed to obtain clinical activity after systemic administration and are able to remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. For more information, please visit www.vcnbiosciences.com.